• 1
    Ilkovitch D, Diana ML. Immune modulation by melanoma-derived factors. Exp Dermatol 2008;17:97785.
  • 2
    Schadendorf D, Paschen A, Sun Y. Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma. Immunol Lett 2000;74:6774.
  • 3
    Alexander MM, Eggermont DS. Melanoma and immunotherapy. Hematol Oncol Clin North Am 2009;23:54764.
  • 4
    Zhao FS, Dou J, Wang J et al. Investigation on the anti-tumor efficacy by expression of GPI- anchored mIL-21 on the surface of B16F10 cells in C57BL/6 mice. Immunobiology 2010;215:89100.
  • 5
    Polak ME, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: the problems of local immunosuppression. Hum Immunol 2009;70:3319.
  • 6
    Atkins MB. Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006;12:2353s8s.
  • 7
    Restifo NP. Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Curr Opin Immunol 2000;12:597603.
  • 8
    Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 2000;18:92734.
  • 9
    Smahel M, Poláková I, Pokorná D. Enhancement of T cell-mediated and humoral immunity of beta-glucuronidase-based DNA vaccines against HPV16 E7 oncoprotein. Int J Oncol 2008;33:93101.
  • 10
    Weihua H, Jing W, Jun D et al. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplatat 2011;20:66980.
  • 11
    Dou J, Chu LL, Zhao FS et al. Study of immunotherapy of murine myeloma by an IL-21-based tumor vaccine in Balb/c mice. Cancer Biol Ther 2007;6:18719.
  • 12
    Ganguly N, Giang PH, Basu SK. Mycobacterium tuberculosis 6-kDa early secreted antigenic target (ESAT-6) protein downregulates lipopolysaccharide induced c-myc expression by modulating the extracellular signal regulated kinases 1/2. BMC Immunol 2007;8:24.
  • 13
    Dou J, Wang YQ, Yu FL et al. Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet 2012;39:18390.
  • 14
    Smyth MJ, Teng MW, Sharkey J. Interleukin 21 enhances antibody-mediated tumor rejection. Cancer Res 2008;68:301925.
  • 15
    Ji JF, Li JH, Lillia MH. Synergistic anti-tumor effect of glycosylpho-sphatidylinositol-anchored IL-2 and IL-12. J Gene Med 2004;6:77785.
  • 16
    Butikofer P, Malherbe T, Boschung M. GPI-anchored proteins: now you see ‘em, now you don't’. FASEB J 2001;15:5458.
  • 17
    Zhao FS, Dou J, He XF et al. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model. Vaccine 2010;28:284652.
  • 18
    Dou J, Liu P, Wang J. Cellular response to gene expression profiles of different hepatitis C virus core protein in Huh-7 cell line with microarray analysis. J Nanosci Nanotechnol 2005;5:20914.
  • 19
    Dou J, Tang Q, Yu FL et al. Investigation of immune effect based on BCG priming and Plasmid DNA expressing Ag85A & GM-CSF boosting in Balb/c mice model. Immunobiology 2010;215:13342.
  • 20
    Hyesung K, Hyemi P, Jungsun P. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model. Vaccine 2010;28:778796.
  • 21
    Groh V, Steinle A, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 1998;279:173740.
  • 22
    Dou J, Wang YF, Wang J et al. Antitumor efficacy induced by human ovarian cancer cells secreting IL-21 alone or combination with GM-CSF cytokines in nude mice model. Immunobiology 2009;214:48392.
  • 23
    He XF, Wang J, Zhao FS et al. . Anti-tumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21 in melanomatous mouse. Immunol Res 2012;52:2409.
  • 24
    Naeem K, Donna B, Rachel B. T cell recognition patterns of immunodominant cytomegalovirus antigens in primary and persistent infection. J Immunol 2007;178:445565.
  • 25
    Rosenberg SA, Sherry RM, Morton KE. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005;175:616976.
  • 26
    Dou J, Wu Y, Wang J et al. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21. Cancer Gene Ther 2010;17:67583.
  • 27
    Atanackovic D, Panse J, Hildebrandt Y. Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologic 2011;96:51220.
  • 28
    Matsui W, Huff CA, Wang Q. Characterization of clonogenic multiple myeloma cells. Blood 2004;103:23326.
  • 29
    Dou J, Pan M, Wen P et al. Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol 2007;4:52833.
  • 30
    Hervé L, Michèle F, Sylvie G. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J Immunol Methods 2001;253:17787.
  • 31
    Ni J, Schirrmacher V, Fournier P. The hemagglutinin-neuraminidase gene of newcastle disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination. Vaccine 2010;28:6891900.
  • 32
    Tseng CW, Monie A, Trimble C. Combination of treatment with death receptor 5-specific antibody with therapeutic HPV DNA vaccination generates enhanced therapeutic anti-tumor effects. Vaccine 2008;26:431419.
  • 33
    Fewkes NM, Mackall CL. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J 2010;6:3928.
  • 34
    Millington KA, Fortune SM, Low J. Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection. Proc Natl Acad Sci USA 2011;108:57305.
  • 35
    Olsen AW, Hansen PR, Holm A. Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 2000;30:172432.
    Direct Link:
  • 36
    K , Shin E, Ayumi Y. targeting apoptotic tumor cells to fcγr provides efficient and versatile vaccination against tumors by dendritic cells. J Immunol 2003;170:16418.
  • 37
    Capitini CM, Fry TJ, Mackall CL. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer. Am J Immunol 2009;5:6583.